Table 1 Association of CK-5/6, CK-14 and CK-17 with clinicopathological features

All

1078

100

129/982

13.1

151/955

15.8

41/931

4.4

Oestrogen receptor

   Negative

266

26.0

67/241

27.8

<0.0005

63/236

26.7

<0.0005

20/236

8.5

0.001

   Positive

757

74.0

56/692

8.1

78/671

11.6

21/650

3.2

Progesterone receptor

   Negative

388

38.0

74/353

21.0

<0.0005

76/348

21.8

<0.0005

26/346

7.5

<0.001

   Positive

633

62.0

49/578

8.5

65/557

11.7

15/538

2.8

Grade

   I

231

21.6

17/194

8.8

<0.0005

32/193

16.6

0.097

3/185

1.6

0.021

   II

453

42.5

43/420

10.2

52/403

12.9

15/391

3.8

   III

383

35.9

69/359

19.2

65/350

18.6

23/347

6.6

T

   1

649

61.3

69/580

11.9

0.159

89/556

16.0

0.790

27/549

4.9

0.434

   2 to 4

409

38.7

58/386

15.0

59/384

15.4

14/366

3.8

N

   0

596

56.6

72/538

13.4

0.607

85/524

16.2

0.477

23/506

4.5

0.659

   1

457

43.4

52/424

12.3

60/413

14.5

16/405

4.0

M

   0

997

96.5

122/910

13.4

0.882

144/885

16.3

0.269

39/861

4.5

0.706

   1

36

3.5

4/32

12.5

3/33

9.1

1/32

3.1

p53

   Negative

772

76.5

76/732

10.4

<0.0005

108/718

15.0

0.264

27/687

3.9

0.120

   Positive

237

23.5

51/230

22.2

40/220

18.2

14/217

6.5

HER2

   Negative

774

84.9

107/756

14.2

0.058

132/740

17.8

<0.0005

34/709

5.7

0.764

   Positive

138

15.1

11/135

9.3

7/133

5.3

5/120

4.2

Age (years)

   ≥50

668

62.0

65/603

10.8

0.006

80/580

13.8

0.033

19/570

3.3

0.045

   <50

410

38.0

64/379

16.9

71/375

18.9

22/361

6.1

BRCA1

46

4.3

6/34

17.6

0.250^b

13/33

39.4

<0.0005^b

1/43

2.3

0.866^b

BRCA2

40

3.7

2/26

7.7

0.599^b

7/26

26.9

0.011^b

0/34

0

0.326^b

Non-BRCA1/BRCA2

358

33.2

44/333

13.2

0.383^b

67/324

20.7

<0.0005^b

11/320

3.4

0.624^b

Two affected

270

25.0

40/253

15.8

0.087^b

30/244

12.3

0.469^b

20/209

9.6

0.001^b

Only sporadic

364

33.8

37/336

11.0

Ref.

34/328

10.4

Ref.

9/325

2.8

Ref.